Omeros (OMER) announced statistical analysis results related to the expanded access program for narsoplimab, Omeros’ ...

Omeros Corporation (Nasdaq: OMER) today announced statistical analysis results related to the expanded access program (EAP) ...

Solid Biosciences Inc. (SLDB) shares surged more than 31% on Tuesday, their best session since January 2024, and extended ...

Solid Biosciences' SGT-003 gene therapy showed strong dystrophin expression, muscle health improvements, and no serious safety concerns in early trial data.

Solid Biosciences has surged back into the Duchenne muscular dystrophy (DMD) gene therapy race. | Solid Biosciences has ...

Solid Biosciences (SLDB) announced initial data from the Phase 1/2 INSPIRE DUCHENNE trial evaluating SGT-003, a next-generation gene therapy ...

Day 90 biopsy data reported from first 3 participants dosed in Phase 1/2 INSPIRE DUCHENNE trial —— Average microdystrophin ...

Omeros Corporation (Nasdaq: OMER) today announced two presentations that will be featured at the 2025 Tandem Meetings – the ...

SAN CARLOS, Calif. - Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company focused on novel cancer treatments, announced today the appointment of Dan Kirby (NYSE:KEX) as Chief ...

From 2018 to 2020, he served as Chief Commercial Officer at Omeros Corporation, overseeing U.S. and EU launch readiness for narsoplimab, a lectin pathway inhibitor, for hematopoietic stem cell ...

The following is a summary of “Steroid-resistant nephrotic syndrome due to renal-limited thrombotic microangiopathy and membranous nephropathy after allogeneic hematopoietic stem cell transplantation ...

Please contact Olivia Walther, owalther@acc.org, for a copy of the paper. Pulmonary Tumor Thrombotic Microangiopathy: A Rapidly Progressive Form of Pulmonary Hypertension in Cancer Patients Hyeon ...